Citadel Advisors’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.33M Sell
63,800
-6,500
-9% -$390K ﹤0.01% 5052
2025
Q4
$4.13M Buy
70,300
+15,400
+28% +$936K ﹤0.01% 4587
2025
Q3
$3.05M Buy
54,900
+16,700
+44% +$895K ﹤0.01% 5278
2025
Q2
$1.97M Buy
38,200
+28,300
+286% +$1.42M ﹤0.01% 5734
2025
Q1
$580K Buy
9,900
+2,000
+25% +$136K ﹤0.01% 8151
2024
Q4
$569K Sell
7,900
-2,600
-25% -$191K ﹤0.01% 8276
2024
Q3
$839K Buy
10,500
+900
+9% +$67.6K ﹤0.01% 7211
2024
Q2
$688K Sell
9,600
-105,500
-92% -$7.76M ﹤0.01% 7390
2024
Q1
$8.1M Sell
115,100
-2,600
-2% -$186K ﹤0.01% 3216
2023
Q4
$9.08M Buy
117,700
+67,400
+134% +$4.44M ﹤0.01% 2981
2023
Q3
$3.42M Buy
50,300
+43,000
+589% +$3.4M ﹤0.01% 4265
2023
Q2
$596K Sell
7,300
-8,200
-53% -$659K ﹤0.01% 7553
2023
Q1
$1.15M Sell
15,500
-8,700
-36% -$671K ﹤0.01% 6470
2022
Q4
$2.01M Buy
24,200
+200
+0.8% +$15.9K ﹤0.01% 5487
2022
Q3
$1.7M Buy
24,000
+9,600
+67% +$830K ﹤0.01% 5896
2022
Q2
$1.25M Sell
14,400
-22,400
-61% -$2.1M ﹤0.01% 6516
2022
Q1
$3.98M Sell
36,800
-10,400
-22% -$1.07M ﹤0.01% 4617
2021
Q4
$6.11M Sell
47,200
-35,200
-43% -$4.32M ﹤0.01% 3945
2021
Q3
$9.98M Sell
82,400
-5,600
-6% -$682K ﹤0.01% 3084
2021
Q2
$9.91M Buy
88,000
+32,400
+58% +$3.41M ﹤0.01% 3092
2021
Q1
$5.31M Buy
55,600
+38,800
+231% +$3.54M ﹤0.01% 4125
2020
Q4
$1.33M Sell
16,800
-16,000
-49% -$1.16M ﹤0.01% 6181
2020
Q3
$2.03M Buy
32,800
+11,600
+55% +$755K ﹤0.01% 4684
2020
Q2
$1.4M Buy
+21,200
New +$1.27M ﹤0.01% 5205
2013
Q3
Sell
-5,600
Closed -$97K 6863
2013
Q2
$97K Buy
+5,600
New +$93K ﹤0.01% 5248

Other funds holding TECH

Citadel Advisors's TECH Position: Q1 2026 in Review

Citadel Advisors reduced its Bio-Techne (TECH) stake by 95% in Q1 2026, selling an estimated $49.4M and leaving 43,402 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #5820.

Citadel Advisors first reported a position in TECH in Q2 2013 and has held it in 51 quarters since. The position peaked at $127M in Q2 2025. 582 funds tracked by Wall St. Rank hold TECH as of Q1 2026.

  • Citadel Advisors held 43,402 shares of Bio-Techne worth $2.27M as of Q1 2026.
  • Citadel Advisors sold 823,318 Bio-Techne shares in Q1 2026, an estimated $49.4M.
  • Bio-Techne made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5820 holding.
  • Citadel Advisors first reported a position in Bio-Techne in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Bio-Techne position peaked at $127M in Q2 2025.
  • 582 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.